Shukra Pharmaceuticals RI review (Neutral)

Shukra Pharmaceuticals Limited Logo

•    SPL is engaged in pharmaceutical product development and marketing.
•    Its operations so far have been on a minuscule level.
•    Though prima facie RI appears lucratively priced, its current market price is purely due to market operations by vested interest parties. 
•    Well-informed/cash surplus investors may consider investing in it, while others may avoid it. 

Shukra Pharmaceuticals Ltd. (SPL) is a fast-growing Indian pharmaceutical company engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally and domestically. Its core strength lies in developing and manufacturing differentiated pharmaceutical products in-house, which it commercializes through marketing infrastructure across geographies. SPL is engaged in the business of manufacturing pharmaceutical products. 

Its product portfolio consists of Tablet and capsules (general) Solid Oral Dosage Form and small volume parenteral- Liquid injection vials and ampules. The company is engaged in domestic as well as international business. With a market presence in PAN India, products of SPL are supplied to developed and developing countries throughout the World. To maintain its competitiveness and to further the cause of health care the company has laid a strong F&D foundation and a WHO, FDA-approved state-of-the-art manufacturing facility near Ahmedabad. SPL is a manufacturing company, so its sales strategy is to sell products in bulk to pharmaceutical marketers and traders who in turn provide the channel for sales to customers. The offer document is silent on its employees' strengths.

The company is coming out with a rights issue of 9394050 equity shares of Rs. 10 each at a fixed price of Rs.20 per share to mobilize Rs. 18.79 cr. The company is offering to the eligible stakeholders 6 shares for every 1 share held as of the record date of February 02, 2023. The issue opens for subscription on February 15, 2023, and will close on February 28, 2023. The amount to be paid on the application is Rs. 5 per share for the number of shares applied. The balance of Rs. 15 is to be paid on one or more subsequent calls by the company from time to time. Post allotment, shares will be listed on BSE. SPL is spending Rs. 0.55 cr. for this RI process and from the net proceedings, it will utilize Rs. 13.54 cr. for working capital, and Rs. 4.70 cr. for general corporate purposes. 

This RI is self-managed by the company itself. Purva Sharegistry (India) Pvt. Ltd. is the registrar of the issue. 

Post RI, SPL's current paid-up equity capital of Rs. 1.57 cr. will stand enhanced to Rs. 9.39 cr. Based on the RI pricing, the company is looking for a market cap of Rs. 18.79 cr. A six-fold jump in equity capital may raise servicing issues.

On the financial performance front, the company has posted a turnover/net profit of Rs. 11.55 cr. / Rs. 0.19 cr. (FY21) and Rs. 20.51 cr. / Rs. 0.75 cr. (FY22). For H1 of FY23, it earned a net profit of Rs. 0.40 cr. on a turnover of Rs. 10.32 cr. 

The offer document is silent on the dividend policy. It will adopt a prudent dividend policy post listings of RI shares based on its financial performance and future prospects. As per BSE web data, the company paid a dividend of 5% for FY19 and FY22. 

The scrip last closed on cum-right basis at Rs. 262.60 on February 01, 2023, and opened on an ex-right basis at Rs. 57.30 on February 02, 2023. Since then, it has marked a high/low of Rs. 76.70 / Rs. 57.30. The scrip last closed at Rs. 76.70 as of February 10, 2023. For the last 52 weeks, it has posted a high/low of Rs. 80.50 / Rs. 11.13. The promoters' holding has been constant at 49.17% for the last three quarters ended on December 31, 2022. The counter is well managed above the RI value by vested interests to lure investors. Its current price is not in line with its financial performance. The counter is currently in ASM ST - Stage 2 and raises major concerns.

Conclusion / Investment Strategy

Though prima facie this RI appears attractively priced at a hefty discount to its current market price, this is purely due to market operations by vested interest parties. A six-fold rise in its paid-up equity capital post-RI may pose servicing issues. Hence well-informed/cash surplus risk takes may consider investors, others may avoid.

Review By Dilip Davda on Feb 13, 2023

Review Author

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on information published here. Any reader taking decisions based on any information published here does so entirely at its own risk. Investors should bear in mind that any investment in stock markets is subject to unpredictable market-related risks. The above information is based on RHP and other documents available as of date coupled with market perception. The author has no plans to invest in this offer.

(SEBI registered Research Analyst-Mumbai).

About Dilip Davda

Dilip Davda, a freelance journalist

Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.

Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.

Email: dilip_davda@rediffmail.com

More Shukra Pharmaceuticals Limited RI Views / Analysis / Recommendations ...

The Shukra Pharmaceuticals Rights Issue 2023 Analysis helps you to understand about the company, offer detail, valuation, capital structure and financial performance. Our SEBI registered Rights Issue Analysts tells you if Shukra Pharmaceuticals Rights Issue 2023 worth investing. The Shukra Pharmaceuticals Rights Issue 2023 Note sets the Rights Issue expectations in systematic way which tells you if Shukra Pharmaceuticals Rights Issue 2023 good to buy (good or bad / yes or no). The Rights Issue Forecast tells you weather to invest in Shukra Pharmaceuticals Rights Issue 2023 by providing Rights Issue recommendations i.e. subscribe, avoid and neutral.


Add a public comment...